Century Financial Statements From 2010 to 2025

IPSC Stock  USD 0.57  0.01  1.72%   
Century Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Century Therapeutics' valuation are provided below:
Gross Profit
4.5 M
Profit Margin
(0.19)
Market Capitalization
50.3 M
Enterprise Value Revenue
1.9555
Revenue
114.9 M
We have found one hundred twenty available fundamental signals for Century Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Century Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of July 31, 2025, Market Cap is expected to decline to about 75.5 M. In addition to that, Enterprise Value is expected to decline to about 71.1 M

Century Therapeutics Total Revenue

6.26 Million

Check Century Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Century Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 32.4 M or Total Revenue of 6.3 M, as well as many indicators such as Price To Sales Ratio of 11.45, Dividend Yield of 0.0 or PTB Ratio of 0.52. Century financial statements analysis is a perfect complement when working with Century Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Century Stock
Check out the analysis of Century Therapeutics Correlation against competitors.
For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

Century Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets343.8 M353.2 M511.7 M
Slightly volatile
Other Current Liabilities27.5 M17.5 M61.8 M
Slightly volatile
Total Current Liabilities81.5 M129.8 M155.6 M
Slightly volatile
Other Liabilities134.7 M128.3 M35.9 M
Slightly volatile
Accounts Payable2.9 M3.1 M21.8 M
Slightly volatile
Cash46.7 M58.4 M29.7 M
Slightly volatile
Other Assets0.860.9M
Slightly volatile
Long Term Debt3.2 M3.4 M79.7 M
Slightly volatile
Other Current Assets2.8 M2.9 M3.8 M
Slightly volatile
Total Liabilities204.9 M191.9 M315.3 M
Slightly volatile
Intangible Assets19.3 M30.8 M26.8 M
Slightly volatile
Property Plant Equipment134.8 M74.5 M219.5 M
Slightly volatile
Property Plant And Equipment Net70.1 M90.8 M29.7 M
Slightly volatile
Non Current Assets Total138.2 M159.2 M59.5 M
Slightly volatile
Non Currrent Assets Other2.6 M3.3 M1.2 M
Slightly volatile
Cash And Short Term Investments193.9 M189.3 M124.1 M
Slightly volatile
Net Receivables778.4 K1.5 M383.2 K
Slightly volatile
Common Stock Total Equity3.6 K6.9 K2.4 K
Slightly volatile
Common Stock Shares Outstanding66.1 M78.6 M57.5 M
Slightly volatile
Short Term Investments135.7 M130.9 M75.8 M
Slightly volatile
Liabilities And Stockholders Equity336.5 M353.2 M186.9 M
Slightly volatile
Non Current Liabilities Total104.1 M62.1 M156.4 M
Slightly volatile
Other Stockholder Equity683.1 M943.4 M358.2 M
Slightly volatile
Long Term Investments57.3 M30.8 M25.4 M
Slightly volatile
Property Plant And Equipment Gross73.4 M126.9 M31 M
Slightly volatile
Total Current Assets198.3 M194.1 M127.3 M
Slightly volatile
Capital Stock5.1 KK2.6 K
Slightly volatile
Net Working Capital61.1 M64.3 M104.1 M
Slightly volatile
Common Stock5.1 KK2.6 K
Slightly volatile
Short and Long Term Debt Total43.2 M53.8 M28.4 M
Slightly volatile
Current Deferred Revenue114.6 M109.2 M17.6 M
Slightly volatile
Short Term Debt3.4 M4.9 M1.3 M
Slightly volatile
Capital Surpluse885.1 M947.9 M806.4 M
Slightly volatile
Short and Long Term Debt4.1 M7.5 M2.3 M
Slightly volatile
Non Current Liabilities Other9.2 M8.7 M2.7 M
Slightly volatile

Century Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative32.4 M33.2 M57 M
Slightly volatile
Research Development62.9 M107.2 M37.9 M
Slightly volatile
Cost Of Revenue12.6 M13.3 M366.1 M
Slightly volatile
Depreciation And Amortization7.9 M13.3 M3.3 M
Slightly volatile
Other Operating Expenses109.4 M144.7 M55.4 M
Slightly volatile
Total Operating Expenses109.4 M144.7 M55.4 M
Slightly volatile
Reconciled Depreciation7.2 M13.3 M3.1 M
Slightly volatile
Income Tax Expense1.1 M1.8 M1.1 M
Very volatile
Tax Provision1.3 M1.8 M404.6 K
Slightly volatile
Interest Income11 M13 M5.9 M
Slightly volatile
Non RecurringMM9.8 M
Slightly volatile
Selling And Marketing Expenses10.4 M11.7 M12.8 M
Slightly volatile

Century Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory115.1 M70.5 M129.3 M
Slightly volatile
Capital Expenditures146.3 K154 K18.4 M
Slightly volatile
Change To Account Receivables43.9 M49.4 M53.8 M
Slightly volatile
End Period Cash Flow60.4 M61.2 M48.4 M
Slightly volatile
Net Borrowings7.8 M8.8 M9.6 M
Slightly volatile
Stock Based CompensationM12.7 M3.3 M
Slightly volatile
Begin Period Cash Flow54.4 M49.3 M39.6 M
Slightly volatile
Depreciation7.4 M13.3 M3.1 M
Slightly volatile
Issuance Of Capital Stock95.8 M74.6 M93 M
Pretty Stable
Change To Netincome9.1 M9.6 M144.5 M
Slightly volatile
Sale Purchase Of Stock23.2 M24.4 M174.3 M
Slightly volatile
Cash And Cash Equivalents Changes23.4 M25.3 M29.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio11.4512.055853.2797
Slightly volatile
Days Sales Outstanding66.0284.200960.6694
Slightly volatile
Stock Based Compensation To Revenue1.831.92562.311
Pretty Stable
Capex To Depreciation0.0110.01167.6564
Slightly volatile
EV To Sales10.7911.35647.7719
Pretty Stable
Payables Turnover1.741.660.5951
Slightly volatile
Sales General And Administrative To Revenue9.795.03196.8755
Slightly volatile
Research And Ddevelopement To Revenue28.7316.276222.1545
Slightly volatile
Capex To Revenue0.02220.02345.1698
Slightly volatile
Cash Per Share2.362.40682.0905
Slightly volatile
Days Payables Outstanding2162271.6 K
Slightly volatile
Intangibles To Total Assets0.07390.08710.0887
Very volatile
Current Ratio1.421.495220.3503
Slightly volatile
Receivables Turnover5.274.33496.226
Slightly volatile
Capex Per Share0.00190.0020.1382
Slightly volatile
Revenue Per Share0.07750.08380.0856
Slightly volatile
Interest Debt Per Share0.520.68440.4845
Slightly volatile
Debt To Assets0.140.15240.1751
Slightly volatile
Days Of Payables Outstanding2162271.6 K
Slightly volatile
Ebt Per Ebit1.070.90330.9891
Pretty Stable
Quick Ratio1.421.495219.8539
Slightly volatile
Net Income Per E B T0.811.01430.9943
Slightly volatile
Cash Ratio0.430.45039.9615
Slightly volatile
Days Of Sales Outstanding66.0284.200960.6694
Slightly volatile
Fixed Asset Turnover0.03820.07250.0462
Very volatile
Debt Ratio0.140.15240.1751
Slightly volatile
Price Sales Ratio11.4512.055853.2797
Slightly volatile
Asset Turnover0.00940.01870.0108
Pretty Stable

Century Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap75.5 M79.4 M955.5 M
Slightly volatile
Enterprise Value71.1 M74.8 M922.9 M
Slightly volatile

Century Fundamental Market Drivers

Cash And Short Term Investments189.3 M

Century Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Century Therapeutics Financial Statements

Century Therapeutics stakeholders use historical fundamental indicators, such as Century Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Century Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Century Therapeutics' assets and liabilities are reflected in the revenues and expenses on Century Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Century Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue109.2 M114.6 M
Total Revenue6.6 M6.3 M
Cost Of Revenue13.3 M12.6 M
Stock Based Compensation To Revenue 1.93  1.83 
Sales General And Administrative To Revenue 5.03  9.79 
Research And Ddevelopement To Revenue 16.28  28.73 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.08  0.08 
Ebit Per Revenue(20.96)(22.01)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:
Check out the analysis of Century Therapeutics Correlation against competitors.
For information on how to trade Century Stock refer to our How to Trade Century Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.27)
Revenue Per Share
1.358
Quarterly Revenue Growth
126.677
Return On Assets
(0.06)
Return On Equity
(0.10)
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.